Patents by Inventor Kyung-Sook Chung
Kyung-Sook Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11732232Abstract: The present disclosure provides a biomimetic cell culture apparatus that mimics interactions among organs in a human body. The present disclosure includes a plurality of culture units for culturing cells, a conduit for connecting the plurality of culture units to each other to form a circulating path, a pump unit disposed on the conduit for forming a flow in culture medium such that the culture medium circulates through the plurality of culture units, and an agitating module for agitating the plurality of culture units.Type: GrantFiled: August 14, 2020Date of Patent: August 22, 2023Assignee: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Cho Rok Jung, Jung Hwa Lim, Hyun Mi Kang, Kyung Hee Noh, Kyung Sook Chung, Mi Young Son, Myung Jin Son
-
Publication number: 20220308045Abstract: The present invention relates to expandable liver organoids, a medium composition for differentiation thereof, and a method for producing liver organoids using the same, and the liver organoids according to the present invention exhibit the characteristics of more mature hepatocytes than 2D differentiated hepatocytes, can be subcultured up to 90 times or more, and exhibit the expandability for maintaining the characteristics of mature hepatocytes even after multiple subcultures, and thus can be usefully utilized for predicting toxicity, regeneration, and inflammatory response, drug screening, and modeling of diseases such as hepatic steatosis.Type: ApplicationFiled: March 4, 2022Publication date: September 29, 2022Inventors: Myung Jin SON, Kyung-Sook CHUNG, Seonju MUN, Jae Sung RYU, Cho-Rok JUNG, Hyun-Soo CHO, Dae Soo KIM
-
Publication number: 20220049205Abstract: The present disclosure provides a biomimetic cell culture apparatus that mimics interactions among organs in a human body. The present disclosure includes a plurality of culture units for culturing cells, a conduit for connecting the plurality of culture units to each other to form a circulating path, a pump unit disposed on the conduit for forming a flow in culture medium such that the culture medium circulates through the plurality of culture units, and an agitating module for agitating the plurality of culture units.Type: ApplicationFiled: August 14, 2020Publication date: February 17, 2022Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Cho Rok JUNG, Jung Hwa LIM, Hyun Mi KANG, Kyung Hee NOH, Kyung Sook CHUNG, Mi Young SON, Myung Jin SON
-
Publication number: 20220000811Abstract: The present invention relates to a composition for hair improvement, and more specifically to a composition for promoting hair growth, or preventing or treating hair loss, comprising a guanine derivative having no toxicity as an active ingredient. The composition has excellent effects of promoting hair growth and regenerating hair follicles, and thus can be effectively used in various fields such as pharmaceutical, food, feed, and cosmetic compositions for promoting hair growth, or preventing, treating, and improving hair loss.Type: ApplicationFiled: November 14, 2019Publication date: January 6, 2022Inventors: Myung Jin SON, Kyung-Sook CHUNG, Sung Wuk KIM, Jiae KOOK, Hong Bum LEE, Sanghee YOO, Youjeong KWQN, Seoniu MUN, Jiwon AHN, Jae Sung RYU
-
Publication number: 20210228463Abstract: Provided is a composition for inhibiting fat formation and reducing body fat, the composition including hydrangenol as an active ingredient. The composition of the present disclosure reduces fat accumulation in adipocytes, reduces phosphorylation of mammalian target of rapamycin (mTOR), and increases phosphorylation of forkhead box O1 (FoxO1), and finally, leading to reduction of an expression level of peroxisome proliferator-activated receptor gamma y (PPAR), and as a result, the composition inhibits formation of triglyceride in adipocytes to exhibit an anti-obesity effect. Accordingly, the composition including hydrangenol disclosed herein as an active ingredient may be usefully applied to the fields of health functional foods or cosmetics for inhibiting fat formation.Type: ApplicationFiled: September 27, 2019Publication date: July 29, 2021Applicant: COSMAX BIO CO., LTD.Inventors: Sun Hee LEE, Yu Kyong SHIN, Hye Shin AHN, Kyung Tae LEE, Kyung Sook CHUNG, Ji Sun SHIN, Hee Soo HAN
-
Publication number: 20210017483Abstract: A cell culture vessel according to the present invention is characterized by comprising a first vessel having a stirring member disposed therein, and a second vessel configured to be inserted in the interior of the first vessel and having a hole for allowing a solvent accommodated in the first vessel to pass through the interior thereof, wherein the stirring member is arranged in a recess portion formed in the first vessel.Type: ApplicationFiled: September 6, 2017Publication date: January 21, 2021Inventors: Sun Woong KANG, Sang Soo HAN, Cho Rok JUNG, Kyung Sook CHUNG
-
Patent number: 9874574Abstract: The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.Type: GrantFiled: June 11, 2014Date of Patent: January 23, 2018Assignees: ANTEROGEN CO. LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyung Sook Chung, Mi Hyung Kim
-
Patent number: 9789114Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: GrantFiled: March 10, 2016Date of Patent: October 17, 2017Assignees: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Publication number: 20170239259Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: ApplicationFiled: December 12, 2014Publication date: August 24, 2017Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Kyeong LEE, Mi Sun WON, Hwan Mook KIM, Song Kyu PARK, Kiho LEE, Ki Hoon LEE, Chang Woo LEE, Jung Joon LEE, Kyung Sook CHUNG, Bo Kyung KIM, Yinglan JIN, Seung-hee LEE
-
Patent number: 9670480Abstract: A method comprising transforming Schizosaccharomyces pombe with a deletion cassette, constructed by four-round serial PCR, block PCR or total gene synthesis, containing a homologous recombination site is provided for preparing gene-targeted heterozygous deletion Schizosaccharomyces pombe. Also provided are gene-targeted hetero2ygous deletion Schizosaccharomyces pombe mutants prepared by the method, and a library of gene-targeted heterozygous deletion Schizosaccharomyces pombe mutants. Further, the library is useful in constructing a method and a kit for screening a drug's modes of action.Type: GrantFiled: August 27, 2008Date of Patent: June 6, 2017Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Kwang Lae Hoe, Dong Uk Kim, Mi Sun Won, Hyang Sook Yoo, Dong Sup Kim, Han Oh Park, Kyung Sook Chung, Young Joo Jang, Mi Young Nam, Sang Jo Han, Shin Jung Choi, Seung Tae Baek, Hyong Bai Kim, Kyung Sun Heo, Hye Mi Lee, Min Ho Lee, Jo Young Park
-
Patent number: 9447063Abstract: The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1?, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, ?-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.Type: GrantFiled: May 28, 2015Date of Patent: September 20, 2016Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi Sun Won, Kyeong Lee, Bo Kyung Kim, Hyun Seung Ban, Seohyun Son, Kyung-Sook Chung
-
Publication number: 20160193215Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: ApplicationFiled: March 10, 2016Publication date: July 7, 2016Inventors: Kyeong LEE, Mi-Sun WON, Hwan-Mook KIM, Song-Kyu PARK, Ki-Ho LEE, Chang-Woo LEE, Bo-Kyung KIM, Hyun-Seung BAN, Kyung-Sook CHUNG, Naik RAVI
-
Publication number: 20160178648Abstract: The present invention relates to: a composition for detecting a marker for detecting the proliferation capacity or treatment capacity of adipose-derived stem cells cultured in a medium containing epidermal growth factor (EGF) or basic fibroblast growth factor (bFGF); and a detection method.Type: ApplicationFiled: June 11, 2014Publication date: June 23, 2016Applicants: ANTEROGEN CO. LTD., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyung Sook CHUNG, Mi Hyung KIM
-
Patent number: 9315507Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: GrantFiled: September 27, 2012Date of Patent: April 19, 2016Assignees: Dongguk University Industry-Academic Cooperation Foundation, Korea Research Institute of Bioscience and BiotechnologyInventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Patent number: 9217149Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: September 3, 2014Date of Patent: December 22, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Publication number: 20150259312Abstract: The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1?, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, ?-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.Type: ApplicationFiled: May 28, 2015Publication date: September 17, 2015Applicants: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Mi Sun WON, Kyeong LEE, Bo Kyung KIM, Hyun Seung BAN, Seohyun SON, Kyung-Sook CHUNG
-
Patent number: 9034327Abstract: Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided.Type: GrantFiled: September 7, 2009Date of Patent: May 19, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Kyung Sook Chung, Mi Sun Won, Ji Won Ahn, Jeong Hae Choi, Hyang Sook Yoo, Young Il Yeom, Eun Young Song, Hee Gu Lee, Jae Hun Cheong, Chang Mo Kang
-
Patent number: 8940936Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: GrantFiled: October 17, 2011Date of Patent: January 27, 2015Assignees: Korea Research Institute of Bioscience and Biotechnology, Dongguk University Industry-Academic Cooperation FoundationInventors: Kyeong Lee, Mi Sun Won, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Ki Hoon Lee, Chang Woo Lee, Jung Joon Lee, Kyung Sook Chung, Bo Kyung Kim, Yinglan Jin, Seung-hee Lee
-
Publication number: 20140371300Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: September 3, 2014Publication date: December 18, 2014Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
-
Patent number: 8846630Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: November 1, 2010Date of Patent: September 30, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song